INTRODUCING CONTIVUE®
An innovative device for continuous medication release into the vitreous.

Roche received CE mark for Contivue, its Port Delivery Platform containing Susvimo, for neovascular age-related macular degeneration (nAMD) in 2025.1
CONTIVUE is a refillable eye implant surgically implanted into the eye during a one-time, outpatient procedure.1-4

Watch the videos to discover Roche's latest innovation in ophthalmology.
What is CONTIVUE and how does it work?
Learn More
How is CONTIVUE implanted in the eye?
Learn More
How does CONTIVUE refill-exchange work?
Learn More
Check eIFU
Important information on CONTIVUE®
  1. CONTIVUE® is an innovative device.2–4
  2. The implant does not clog when implanted in the eye.2
  3. The implant provides continuous release of ranibizumab over an extended period of time.2–7
  4. A dose response was observed across the PDS treatment arms, with patients in the PDS 100 mg/mL arm experiencing the greatest clinical benefit, similar to monthly intravitreal ranibizumab 0.5 mg injections.2,6
  5. PDS 100 mg/mL Q24W regimen is non-inferior and equivalent to the intravitreal ranibizumab 0.5 mg regimen as measured by the change from baseline in BCVA at the average of Week 36 and Week 40.5
  6. The initial fill needle, refill needle, insertion tool assembly and explant tool performed as intended to fill, refill, insert, and remove the implant (if needed).8
  7. The implant-insertion procedure and refill-exchange procedure are generally well tolerated.2
  8. The safety of the devices and procedures have been sufficiently characterised, are manageable, and are being continuously analysed.8,9
  9. The long-term tolerability of the implant has been well established through the long duration of our current clinical follow-up.2,6
  10. If clinically indicated, though rare, the steps to perform the explantation procedure have been established and their optimisation are continually being assessed.2
  11. Serious adverse events related to refill-exchange procedure or refill needle occurred in <10% of patients throughout their implant exposure (mean ~7.6 refill-exchanges). See claim 7 above.
  12. Serious adverse events related to implant removal procedure or explant tool occurred in <1% of patients. See claim 10 above.
  1. Roche. Roche receives CE mark for Contivue, its Port Delivery Platform containing Susvimo, for neovascular age-related macular degeneration (nAMD). 2025 [Internet; cited November 2025]. Available from: https://www.roche.com/media/releases/med-cor-2025-09-04. 
  2. Campochiaro PA, et al. Ophthalmology. 2019;126:1141–1154. 
  3. Regillo C, et al. Ophthalmology. 2023;130:735–747. 
  4. Campochiaro PA, et al. Ophthalmol Retina. 2025;9:144–155. 
  5. Holekamp NM, et al. Ophthalmology. 2022;129:295–307. 
  6. Khanani AM, et al. JAMA Ophthalmol. 2025;143:326–335. 
  7. Pieramici DJ, et al. JAMA Ophthalmol. 2025;143:317–325. 
  8. Khanani AM, et al. Ophthalmic Surg Lasers Imaging Retina. 2022;53:257–265. 
  9. Pieramici DJ, et al. Transl Vis Sci Technol. 2025;14:8.
Roche Pharma (Schweiz) AG übernimmt keine Verantwortung für die Richtigkeit, die Rechtmässigkeit oder den Inhalt der externen Seite oder der nachfolgenden Links. Mit dem Verlassen des Schweizer HCP-Portals, akzeptieren Sie, dass die Informationen auf externen Seiten möglicherweise nicht mit der in der Schweiz zugelassenen Anwendung des Produkts übereinstimmen. Die Schweizer Fachinformation ist die primäre Informationsquelle für Schweizer HCPs. Wenden Sie sich an die externe Seite, wenn Sie Fragen zu deren Inhalt haben.
Restricted

Das Setzen von Lesezeichen ist nur für eingeloggte Benutzer möglich.

Registrierung Anmeldung